Lamivudina + Zidovudina Mylan (Zidovudine, Lamivudine)

Both drugs are nucleoside analogues that are converted inside cells to active triphosphate forms. These active metabolites compete with natural nucleosides for incorporation into the viral DNA chain by HIV reverse transcriptase, causing premature chain termination and blocking viral replication.

The exact dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, weight, renal function, and the overall antiretroviral regimen. Healthcare providers follow national and WHO guidelines to individualise therapy.

Safety in pregnancy and lactation has not been fully established. The drug may be used when the potential benefit to the mother outweighs potential risks to the fetus or infant. Clinicians should discuss risks and benefits with the patient and consider alternative regimens when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Zidovudine/lamivudine is a well‑established NRTI combination with a long safety record. Compared with newer agents, it may have a higher incidence of hematologic side effects but remains a cost‑effective option, especially in resource‑limited settings and when used in fixed‑dose combinations.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. It must be kept away from moisture, excessive heat and direct sunlight to maintain stability and potency.

The medication is taken orally, usually with food or a glass of water to reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider and should not alter the regimen without medical advice.

Serious adverse events include severe anemia or neutropenia, lactic acidosis with hepatic steatosis, and hypersensitivity reactions such as rash or Stevens‑Johnson syndrome. Prompt medical evaluation is required if any of these symptoms develop.

Patients with known hypersensitivity to zidovudine, lamivudine, or any excipients in the formulation should avoid the product. Caution is also advised for individuals with pre‑existing severe bone‑marrow suppression, hepatic impairment, or those receiving contraindicated drug combinations.